Demystifying Tech M&A Valuation
Selling Your Healthcare or Life Sciences Company
This whitepaper gives medical groups, life sciences, and healthcare companies in the lower middle market an understanding of financing and M&A alternatives available, the role of financial buyers, key issues around selling equity in your business, and the typical financing and M&A process.
This whitepaper shares the most common scenarios that arise when you are selling your company, the choices you have when negotiating the terms of the sale, and which choices are your best ones, as supported by academic research are covered.
Pullan's Pieces - A Business Development View of the Oncology Landscape
In this whitepaper, biopharma partnering expert and Life Sciences consultant, Linda Pullan, PhD, explores the current oncology landscape and offers insightful perspective on trends, pipeline by indication, dealmaking, and the top ten oncology companies and the drugs they’re developing.
Must-Know Finance Concepts for Life Sciences Valuations
The Nuts & Bolts of Due Diligence in Biopharma Partnering
What's Hot and What's Not in Oncology Licensing in 2020?
How to Win at the Partnering Game
In this white paper, Linda Pullan provides a review of the rules of the partnering game – whether it’s partnering from preclinical to late clinical development – to provide an understanding of what to expect in moving from introductions to negotiations of a license or acquisition and how to win with a clear strategy.
Earnouts: Structures for Breaking Negotiation Deadlocks
This white paper features Senior M&A Executive Javier Enrile of Principal Global Investors. Mr. Enrile provides his extensive expertise to explain how earnout, (also "earn-out") structures work and how it can reduce risk for the buyer, add attractive incentives for the seller, and serve to break negotiation deadlocks and get deals consummated.
Preparing For Your Exit
Precision Medicine in Central Nervous System Drug Development